Analysis of a Candida auris Outbreak Provides New Insights into an Emerging Pathogen

对耳念珠菌疫情的分析为新出现的病原体提供了新的见解

阅读:4

Abstract

Candida auris is an emerging human fungal pathogen that is being increasingly linked to outbreaks. It is concerning to health care workers because of its high mortality rate, due primarily to its antifungal resistance. Among the tools being developed to study this yeast are large cohorts of regional isolates, which can be useful for studying epidemiology, antifungal susceptibility patterns, and diagnostic methods. In this issue of the Journal of Clinical Microbiology, Y. Zhu, B. O'Brien, L. Leach, A. Clarke, et al. (J Clin Microbiol 58:e01503-19, 2020, https://doi.org/10.1128/JCM.01503-19) describe the laboratory findings of a collection of isolates from a large outbreak of C. auris obtained from numerous health care facilities in the New York area. Real-time PCR was used as a screening tool with great accuracy, while internal transcribed spacer (ITS) and D1/D2 sequencing were successfully employed for isolate clade assignment. South Asia clade I was identified as the major genotype, while South American clade IV was a minor genotype. Surveillance isolates from patients confirmed axilla/groin and nare colonization; however, results of quantitative analysis of fungal burdens showed that when the nares are colonized, burdens are significantly higher than for axilla/groin colonization. Antifungal susceptibility testing was in agreement with past studies. High levels of fluconazole resistance were detected, while few isolates were resistant to echinocandins. Resistance to multiple antifungals was frequent, and three isolates were recovered that appeared to be pan-resistant. This type of study is yet another useful tool for investigating C. auris, which is becoming an increasingly important human fungal pathogen that should be monitored very closely.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。